MedTrace Logo

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

NCT03293173 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-06-21

No results posted yet for this study

Summary

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

COMBINATION_PRODUCT

R-CHOEP

rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone

COMBINATION_PRODUCT

DA-EPOCH-R

dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab

Sponsors & Collaborators

  • Helsinki University Central Hospital

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Nordic Lymphoma Group

    lead NETWORK

Principal Investigators

  • Sirpa Leppa, prof · Helsinki University Hospital Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-04
Primary Completion
2021-01-31
Completion
2024-12-31

Countries

  • Denmark
  • Finland
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03293173 on ClinicalTrials.gov